Lankenau Institute for Medical Research

Syncromune to Present Phase 1 Data on Novel SYNC-T Therapy for Metastatic Prostate Cancer at ASCO 2025

- Syncromune will present Phase 1 clinical data on its SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer at the ASCO Annual Meeting on May 31, 2025. - SYNC-T is a potentially first-in-class platform immunotherapy that synchronizes tumor antigens, immune cells, and a multi-target biologic drug directly in the tumor microenvironment. - The therapy employs a proprietary device delivery system that lyses tumor cells to release antigens and then infuses a biologic drug, aiming to activate T cells against cancer throughout the body.